NovaBay Pharmaceuticals, Inc. (NBY)
NBY Stock Price Chart
Explore NovaBay Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze NBY price movements and trends.
NBY Company Profile
Discover essential business fundamentals and corporate details for NovaBay Pharmaceuticals, Inc. (NBY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Oct 2007
Employees
13.00
Website
https://novabay.comCEO
Justin M. Hall
Description
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
NBY Financial Timeline
Browse a chronological timeline of NovaBay Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.21.
Dividend declared on 30 Sept 2025
A dividend of $0.80 per share was announced, adjusted to $0.80.
Earnings released on 14 Aug 2025
EPS came in at -$0.34 falling short of the estimated -$0.21 by -61.90%.
Earnings released on 15 May 2025
EPS came in at -$0.61 falling short of the estimated -$0.24 by -154.17%.
Earnings released on 25 Mar 2025
EPS came in at -$33.22 falling short of the estimated -$0.19 by -17.38K%, while revenue for the quarter reached $2.31M , missing expectations by -7.64%.
Earnings released on 7 Nov 2024
EPS came in at -$0.60 falling short of the estimated -$0.28 by -114.29%, while revenue for the quarter reached $2.44M , missing expectations by -2.36%.
Earnings released on 13 Aug 2024
EPS came in at -$1.37 falling short of the estimated -$1.23 by -11.38%, while revenue for the quarter reached $2.40M , missing expectations by -23.81%.
Stock split effective on 31 May 2024
Shares were split 1 : 35 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 May 2024
EPS came in at -$4.90 falling short of the estimated -$0.15 by -3.17K%, while revenue for the quarter reached $2.63M , missing expectations by -19.79%.
Earnings released on 26 Mar 2024
EPS came in at -$33.22 falling short of the estimated -$0.30 by -10.97K%, while revenue for the quarter reached $3.73M , beating expectations by +9.62%.
Earnings released on 9 Nov 2023
EPS came in at -$12.94 falling short of the estimated -$0.40 by -3.13K%, while revenue for the quarter reached $3.26M , missing expectations by -9.83%.
Earnings released on 10 Aug 2023
EPS came in at -$44.41 falling short of the estimated -$0.56 by -7.83K%, while revenue for the quarter reached $4.61M , beating expectations by +8.73%.
Earnings released on 11 May 2023
EPS came in at -$29.72 falling short of the estimated -$0.91 by -3.17K%, while revenue for the quarter reached $3.12M , missing expectations by -2.38%.
Earnings released on 30 Mar 2023
EPS came in at -$151.40 falling short of the estimated $0.17 by -89.16K%, while revenue for the quarter reached $3.64M , missing expectations by -28.57%.
Stock split effective on 16 Nov 2022
Shares were split 1 : 35 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2022
EPS came in at -$122.26 falling short of the estimated -$1.23 by -9.84K%, while revenue for the quarter reached $3.83M , beating expectations by +2.03%.
Earnings released on 11 Aug 2022
EPS came in at -$48.90 falling short of the estimated -$1.40 by -3.39K%, while revenue for the quarter reached $3.05M , missing expectations by -13.00%.
Earnings released on 12 May 2022
EPS came in at -$1.75 falling short of the estimated -$1.05 by -66.67%, while revenue for the quarter reached $2.63M , missing expectations by -19.11%.
Earnings released on 29 Mar 2022
EPS came in at -$24.45 falling short of the estimated -$1.75 by -1.30K%, while revenue for the quarter reached $2.64M , missing expectations by -21.05%.
Earnings released on 11 Nov 2021
EPS came in at -$61.13 falling short of the estimated -$1.40 by -4.27K%, while revenue for the quarter reached $1.84M .
Earnings released on 12 Aug 2021
EPS came in at -$48.90 falling short of the estimated -$1.40 by -3.39K%, while revenue for the quarter reached $2.13M , beating expectations by +6.65%.
Earnings released on 6 May 2021
EPS came in at -$48.90 falling short of the estimated -$1.40 by -3.39K%, while revenue for the quarter reached $1.81M , missing expectations by -22.78%.
Earnings released on 25 Mar 2021
EPS came in at -$48.90 , while revenue for the quarter reached $1.89M .
Earnings released on 12 Nov 2020
EPS came in at -$97.80 falling short of the estimated -$1.40 by -6.89K%, while revenue for the quarter reached $2.17M , missing expectations by -9.09%.
NBY Stock Performance
Access detailed NBY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.